Stockholm August 16, 2023
BioLamina AB BioLamina announces appointment of new management team members
BioLamina is pleased to announce the appointment of Dr. Mattias Gäreskog as the new Chief Commercial Officer (CCO) and of Lotta Larsson as the new Head of People.
Dr. Gäreskog brings a wealth of experience from the commercial field, with more than 15 years in commercial roles at Mercodia AB, including most recently as Managing Director Marketing & Sales. Having previously served as Business Development Manager within BioLamina, he possesses a comprehensive understanding of the company’s operations, market dynamics and customers. He also holds a PhD from Uppsala University, Sweden, where he explored the biological pathways leading to diabetic complications and possible treatments of adverse effects.
Lotta Larsson has a solid 15-year experience of establishing and running a global HR function in a fast-growing, international and life science environment. Before joining BioLamina, she was the Global HR Manager of the medtech company RaySearch Laboratories AB, where she successfully accompanied their upscaling journey. She holds two Bachelors of Applied Science, in Health Sciences Health Promotion and Dietetics and Clinical Nutrition, from the University of Melbourne, Australia.
“We are thrilled to welcome Mattias and Lotta in the management team. As we continue to pursue our vision of becoming the leading provider of primary cell culture solutions to enable life-saving therapies, I feel confident that the breadth of their experience and expertise, their leadership qualities and values will allow them to develop both their teams as well as the overall company.”Veronica Byfield Sköld, CEO of BioLamina
“It is an honor to lead the commercial unit of such a fantastic company as BioLamina. I am looking forward to driving our commercial efforts going forward and to helping the team reach new heights. Contributing to improving global health has always been important to me and what could be better than being part of BioLamina’s journey within the rapidly evolving cell therapy market!”Dr. Mattias Gäreskog, the new CCO
“I am excited to join BioLamina as the new Head of People during this critical phase of upscaling. Our employees are the driving force behind BioLamina’-s achievements and I am dedicated to ensuring that we continue to nurture our talent, keep fostering inclusiveness, and retain our values, so that our people continue to be at the forefront of our growth story.”Lotta Larsson, the new Head of People
For more information, please contact:
Veronica Byfield Sköld, CEO
Phone: +46 73 073 39 33
We think you might be interested in…
Management Team Board Members Key shareholders Shareholder % of total shares outstanding Bure Growth
Biolamina matrices enable scientific progress Whether for disease modeling or preparing cells for cl
News & Events
Other resources Popular applications
BioLamina AB is a Swedish biotechnology company built on a scientific foundation and a legacy in matrix biology and cell culture-based research. Our flagship products, the biorelevant human recombinant laminin isoforms Biolaminin®, are defined cell culture matrices that successfully imitate the natural, cell-specific cell-matrix interaction in the cell culture dish, allowing cells to thrive and maintain their function. Our products are a powerful resource for scientists working with stem cells and primary cells both within basic research as well as in regenerative medicine companies with a focus on cell therapy applications.